CARM (CARISMA Therapeutics) Tariff Resilience Score: 6/10 (As of Jul. 07, 2026)


What is CARISMA Therapeutics Tariff Resilience Score?

CARISMA Therapeutics CARM -3.28% Tariff Resilience Score is 6 as of Jul. 07, 2026. The stock has 3 warning signs investors should review. Among 1,369 Biotechnology companies, CARISMA Therapeutics ranks better than 75.89% on this metric.

CARISMA Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

CARISMA Therapeutics has Biotech company with potential exposure to tariffs on imported raw materials and equipment. However, its niche focus and potential for alternative suppliers provide some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CARISMA Therapeutics might have Average Resilient.

CARISMA Therapeutics  (OTCPK:CARM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CARISMA Therapeutics Tariff Resilience Score Related Terms

CARM vs SCPX, CYTOF, CNBX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
CARISMA Therapeutics (CARM) has a Tariff Resilience Score of 6 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CARISMA Therapeutics ranks #330 out of 1369 companies in the Biotechnology industry, placing it in the top 24.1%.
Is CARISMA Therapeutics' Tariff Resilience Score too high?
CARISMA Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. CARISMA Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, CARISMA Therapeutics ranks #330 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CARISMA Therapeutics' Tariff Resilience Score compare to SCPX and CYTOF?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #330 out of 1369 companies for Tariff Resilience Score. This places CARISMA Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CARISMA Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CARISMA Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARISMA Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Tariff Resilience Score is 6 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.